125 related articles for article (PubMed ID: 9845407)
1. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules.
Sharma VK; Ugheoke EA; Vasudeva R; Howden CW
Aliment Pharmacol Ther; 1998 Nov; 12(11):1171-4. PubMed ID: 9845407
[TBL] [Abstract][Full Text] [Related]
2. Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy.
Sharma VK; Heinzelmann EJ; Steinberg EN; Vasudeva R; Howden CW
Am J Gastroenterol; 1997 May; 92(5):848-51. PubMed ID: 9149199
[TBL] [Abstract][Full Text] [Related]
3. Simplified lansoprazole suspension--a liquid formulation of lansoprazole--effectively suppresses intragastric acidity when administered through a gastrostomy.
Sharma VK; Vasudeva R; Howden CW
Am J Gastroenterol; 1999 Jul; 94(7):1813-7. PubMed ID: 10406240
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
5. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Katz PO; Hatlebakk JG; Castell DO
Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
[TBL] [Abstract][Full Text] [Related]
6. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Bell NJ; Hunt RH
Aliment Pharmacol Ther; 1996 Dec; 10(6):897-904. PubMed ID: 8971286
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Takeda H; Hokari K; Asaka M
J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
[TBL] [Abstract][Full Text] [Related]
8. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
[TBL] [Abstract][Full Text] [Related]
10. The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole.
Sharma VK; Vasudeva R; Howden CW
Aliment Pharmacol Ther; 1999 Aug; 13(8):1091-5. PubMed ID: 10468686
[TBL] [Abstract][Full Text] [Related]
11. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.
Verdú EF; Fraser R; Armstrong D; Blum AL
Scand J Gastroenterol; 1994 Dec; 29(12):1065-9. PubMed ID: 7886393
[TBL] [Abstract][Full Text] [Related]
12. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
13. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.
Brummer RJ; Geerling BJ; Stockbrügger RW
Dig Dis Sci; 1997 Oct; 42(10):2132-7. PubMed ID: 9365148
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
[TBL] [Abstract][Full Text] [Related]
15. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
17. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
Geus WP; Mulder PG; Nicolai JJ; Van den Boomgaard DM; Lamers CB
Aliment Pharmacol Ther; 1998 Apr; 12(4):329-35. PubMed ID: 9690721
[TBL] [Abstract][Full Text] [Related]
18. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
